Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Using dexmedetomidine to reduce postoperative delirium in brain tumor patients

Official title: Effect of Perioperative Dexmedetomidine on Postoperative Delirium in Patients With Brain Tumors: a Randomized Placebo-controlled Trial

Run by Beijing Tiantan Hospital · NCT06164314 · Data updated 2026-11-12

This study is testing if a medication called dexmedetomidine can help prevent confusion and delirium in patients having brain surgery for a tumor.

More Postoperative Delirium trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment366 (estimated)
SponsorBeijing Tiantan Hospital
Academic / other
Locations1 site (Beijing)
StatusRecruiting
StartedJanuary 25, 2024
Main results expectedSeptember 30, 2026
Study endsSeptember 30, 2026
Registry record updatedFebruary 17, 2025
Trial IDNCT06164314 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults aged 18 and older with temporal glioma scheduled for elective craniotomy.

Probably not a fit

Patients with severe preoperative cognitive impairment or those with a history of traumatic brain injury or previous neurosurgery may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effects of dexmedetomidine on reducing the incidence of postoperative delirium in patients undergoing elective craniotomy for temporal glioma. The study will involve strict adherence to protocols, with data collected and monitored securely in an electronic database. The primary hypothesis is that dexmedetomidine can mitigate neuroinflammation, enhance postoperative pain management, and improve sleep quality, thereby decreasing the likelihood of delirium after surgery.

Why it matters

Potential benefit: If successful, this approach could significantly reduce the occurrence of postoperative delirium, improving recovery outcomes for patients with brain tumors.

How similar studies have gone: While the use of dexmedetomidine in this context is promising, further studies are needed to confirm its efficacy, as similar approaches have shown mixed results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Patients with temporal glioma scheduled for a elective craniotomy
* Age ≥18 years
* Obtain written informed consent.

Exclusion Criteria:

* Patients with severe preoperative cognitive impairment
* History of traumatic brain injury or previous neurosurgery
* History of psychotropic medications
* Allergy to dexmedetomidine
* Pregnant or lactating women
* History of obstructive sleep apnoea syndrome
* Severe bradycardia(heart rate \<40 beats/min), sick sinus syndrome or second-to-third degree atrioventricular block
* Severe hepatic dysfunction
* Severe renal dysfunction

Where it's running

  • Beijing Tiantan Hospital
    Beijing, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.